Evidence map›Paper›PMID 42309581›Full record

ArticleJournal, genetic engineering & biotechnology2026

Evaluation of CRISPR/Cas9 based single and multiplex gRNAs against ChiLCV in tobacco.

L C Sushmitha, Arpita Srivastava, R K Yadav, Anirban Roy, Shipra Saxena, Navinder Saini, P K Jain, T K Behera, Manisha Mangal

Abstract read
In one paragraph

Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

L C SushmithaDivision of Vegetable Science, ICAR-Indian Agricultural Research Institute, New Delhi, India.
Arpita SrivastavaDivision of Vegetable Science, ICAR-Indian Agricultural Research Institute, New Delhi, India.
R K YadavDivision of Vegetable Science, ICAR-Indian Agricultural Research Institute, New Delhi, India.
Anirban RoyDivision of Plant Pathology, ICAR-Indian Agricultural Research Institute, New Delhi, India.
Shipra SaxenaXenesis, Absolute, Gurugram, Haryana, India.
Navinder SainiDivision of Genetics, ICAR-Indian Agricultural Research Institute, New Delhi, India.
P K JainICAR-National Institute for Plant Biotechnology, New Delhi, India.
T K BeheraICAR-Indian Institute of Horticultural Research, Bengaluru, Karnataka, India.
Manisha MangalDivision of Vegetable Science, ICAR-Indian Agricultural Research Institute, New Delhi, India. Electronic address: manishamangal@rediffmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chilli leaf curl virus (ChiLCV), a whitefly-transmitted monopartite begomovirus, causes severe yield losses in chilli-growing regions worldwide. This study evaluated the efficiency of single and multiplex CRISPR/Cas9 gRNAs in targeting key coding regions of ChiLCV genome in Nicotiana benthamiana. Four guide RNAs (gRNAs) specific to the CP, C3/C2, C2/C1, and Rep coding regions, were designed and assembled into four single-gRNA expression constructs, each targeting one viral region at a time, and six dual-gRNA constructs, each simultaneously targeting two viral regions. Agroinfiltration assays showed that all constructs reduced viral DNA, with dual-gRNA combinations achieving stronger suppression than single gRNAs. The gRNA1 + gRNA4 dual combination, targeting CP and Rep genes, was the most effective, reducing viral titre by 49.3% at 4 dpi and 47.9% at 20 dpi in systemic leaves. Viral accumulation was quantified using qPCR, disease severity was assessed phenotypically, and gRNA/Cas9 expression was confirmed by qRT-PCR, while HRM analysis verified targeted genome modifications. Overall, the results demonstrate that dual-gRNA constructs efficiently suppress viral replication, reduce disease severity, and induce precise genome edits, underscoring the potential of multiplexed CRISPR/Cas9 for developing durable resistance against ChiLCV.

Indexed as

ChiLCVCRISPR/Cas9Nicotiana benthamianaTransient expression

Identifiers

PMID42309581
PMCPMC13011193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.